LL-37

What it is

LL-37 is a human antimicrobial peptide derived from the cathelicidin family — a natural defence molecule produced by immune and epithelial cells.

It supports the body’s first immune barrier, helping to protect against bacteria, fungi, and viruses while influencing inflammation and tissue repair.

Key benefits

Broad antimicrobial defence: Active against multiple pathogens including bacteria, fungi, and enveloped viruses.
Immune modulation: Helps the immune system mount a balanced response rather than chronic inflammation.
Tissue repair: Promotes angiogenesis and epithelial regeneration.
Respiratory and skin protection: Studied in chronic wounds, respiratory infections, and gut lining health.
Synergy with Thymosin Alpha-1: Combined use may reduce LL-37’s cytotoxicity and improve immune balance.

How it works (in simple terms)

LL-37 is a by-product of a larger protein (cathelicidin) that is activated by vitamin D.

When released, it binds to microbial membranes and disrupts them, while also sending repair signals to immune cells.

Its effectiveness depends on proper vitamin D levels, as low conversion (25-OH to 1,25-OH) can limit LL-37 activity.

Important considerations

Cytotoxicity: Prolonged or high-dose exposure may damage healthy cells.
Microdosing is recommended — smaller, pulsed doses are preferred to avoid toxicity.
Air pollution and oxidative stress can inhibit LL-37 expression, reducing its natural protective role.
Xylitol has been noted in research as a compound that may support natural LL-37 activity in the airways.
Thymosin Alpha-1 is often paired with LL-37 to help counteract potential inflammatory or cytotoxic responses.

Forms & typical use

Subcutaneous injection: Main research route.
Nasal spray (25–50 mcg per spray): Explored experimentally for respiratory health.

Research dosing overview

Microdosing range: 100–400 mcg per day (divided doses).
Higher doses may increase cytotoxicity or inflammation — short cycles are advised.
Use selectively and locally where immune activation is required.
Injection-site irritation can occur; dilute with additional bacteriostatic water to reduce stinging.

For research and educational reference only — LL-37 is not an approved therapeutic product.

Smart peptide combinations

LL-37 + Thymosin Alpha-1 (Tα1): Hybrid pairing; Tα1 may reduce LL-37-induced inflammation.
LL-37 + BPC-157: Combines antimicrobial and gut-lining repair effects.
LL-37 + TB-500: For wound healing and epithelial regeneration.
LL-37 + Epitalon: Explored for immune and circadian balance.

Research summary

LL-37 expression is vitamin D-dependent; deficiency reduces its natural production.
Cytotoxicity has been observed in cell models with sustained or high-dose exposure.
Animal and preliminary human studies support antimicrobial and wound-healing potential.
Sensitivity varies — some individuals experience inflammatory or digestive responses.